Gen Surg SAQs · surgical-critical-care
Bleeding after damage-control laparotomy — activate, ratio, TXA, fibrinogen and calcium
Fellowship SAQ on surgical massive transfusion: MTP triggers and scores, PROPPR ratios with plasma-first sequencing, CRASH-2 TXA timing, CRYOSTAT-2 fibrinogen restraint, calcium replacement and whole-blood selection.
On this page
Study tools
Target exams
Write your answer
Saved on this device. No marking — you are the marker.
Model answer
(A) Activate now on physiology — balanced 1:1:1 fast with plasma early (4 marks). Hypotension with ongoing drain output after 3 units meets clinical MTP triggers — and among trigger-meeting patients, even 1 to 3 units carry no excess harm signal, so activation cannot be called over-triage in retrospect.[9] Score it formally: TASH is the most well validated trigger score, ABC balances accuracy with ease where laboratories lag, and shock index runs on vitals alone with fair performance — use all three layers, and transfuse while tallying.[6] Resuscitate 1:1:1 plasma-platelets-red cells during active bleeding per PROPPR (338 vs 342 patients; exsanguination 9.2% vs 14.6%, haemostasis 86% vs 78%, with 23 complications equal) — within the accepted 1:1:1 to 1:1:2 protocol range — sequencing plasma early (red-cell-first carries worse adjusted 6-hour, 24-hour and in-hospital mortality) and delivering fast, because shorter time to blood means better outcomes.[1][25][8]
(B) TXA now — 1 g load inside the 2-hour window; fibrinogen only if the level with bleeding justifies it (3 marks). Injury was 2 hours ago, so give TXA 1 g loading over 10 minutes then 1 g over 8 hours immediately: CRASH-2 dosing cut all-cause death (14.5% vs 16.0%) and bleeding death (4.9% vs 5.7%).[2] Timing is the whole decision — within 1 hour RR 0.68, 1 to 3 hours RR 0.79, after 3 hours harm RR 1.44 — and the pooled optimal criterion is treatment within 2 hours of injury, which he still meets.[3][4] For low fibrinogen with active bleeding, replace by local protocol for documented hypofibrinogenaemia — but do not protocolise empirical cryoprecipitate for every activation (no verified threshold is quoted here; use your protocol's number): CRYOSTAT-2 (3 pools, 6-g equivalent, within 90 minutes) gave 28-day death 25.3% vs 26.1% with equal thrombosis, and the 5-trial meta-analysis found 24% vs 25% (OR 1.03).[10][11]
(C) Calcium 0.94 is low — replace under load and recheck; whole blood suits his pressure; watch for early PE (3 marks). Ionised 0.94 meets the verified hypocalcaemia threshold (1.0 or less): plasma transfusion raised hypocalcaemia to 53% vs 36% with severe lows tied to decreased survival — yet arrival means sit at 1.08 regardless of transfusion, so his level reflects shock plus citrate and earns replacement with rechecks each round, consistent with the whole-blood dosing signal (1 g or more calcium chloride per 2 units, OR 0.164 for 24-hour death).[14][16][15] At systolic pressure 82 he sits in the whole-blood-benefit subgroup (below-90 aOR 0.72) — offer low-titre O whole blood first where available, otherwise reconstituted 1:1:1, stating the observational limit aloud.[19] From haemostasis, start mechanical VTE prophylaxis and convert to pharmacologic cover promptly: 13% of PROPPR patients developed VTE with pulmonary embolus predominant in the first 72 hours.[21]
References15ShowHide
- [1]Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA, 2015.PMID 25647203
- [2]Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet, 2010.PMID 20554319
- [3]Roberts I, Shakur H, Afolabi A, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet, 2011.PMID 21439633
- [4]Osawa I, Goto T, Roberts I, et al. Tranexamic acid for trauma: optimal timing of administration based on the CRASH-2 and CRASH-3 trials. Br J Surg, 2025.PMID 40277024
- [6]Shih AW, Al Khan S, Wang AY, et al. Systematic reviews of scores and predictors to trigger activation of massive transfusion protocols. J Trauma Acute Care Surg, 2019.PMID 31454339
- [8]Meneses E, Boneva D, McKenney M, et al. Massive transfusion protocol in adult trauma population. Am J Emerg Med, 2020.PMID 33071074
- [9]Gelbard RB, Griffin RL, Reynolds L, et al. Over-transfusion with blood for suspected hemorrhagic shock is not associated with worse clinical outcomes. Transfusion, 2022.PMID 35753037
- [10]Davenport R, Curry N, Fox EE, et al. Early and Empirical High-Dose Cryoprecipitate for Hemorrhage After Traumatic Injury: The CRYOSTAT-2 Randomized Clinical Trial. JAMA, 2023.PMID 37824155
- [11]Burt T, Guilliam A, Cole E, et al. Effect of early administration of fibrinogen replacement therapy in traumatic haemorrhage: a systematic review and meta-analysis of randomised controlled trials with narrative synthesis of observational studies. Crit Care, 2025.PMID 39875966
- [14]Moore HB, Tessmer MT, Moore EE, et al. Forgot calcium? Admission ionized-calcium in two civilian randomized controlled trials of prehospital plasma for traumatic hemorrhagic shock. J Trauma Acute Care Surg, 2020.PMID 32317575
- [15]Rajesh A, Barry L, Limon D, et al. Aggressive calcium chloride dosing reduces early mortality in trauma patients receiving whole blood resuscitation. J Trauma Acute Care Surg, 2026.PMID 41995161
- [16]Rushton TJ, Tian DH, Baron A, et al. Hypocalcaemia upon arrival (HUA) in trauma patients who did and did not receive prehospital blood products: a systematic review and meta-analysis. Eur J Trauma Emerg Surg, 2024.PMID 38319350
- [19]Torres CM, Stolarski AE, Kenzik KM, et al. Identifying trauma patients who benefit from whole blood transfusion: An effect decomposition analysis on patient survival. Transfusion, 2025.PMID 40717387
- [21]Myers SP, Brown JB, Leeper CM, et al. Early versus late venous thromboembolism: A secondary analysis of data from the PROPPR trial. Surgery, 2019.PMID 31230842
- [25]Hynes AM, Westein RJ, Turner TJ, et al. Fresh frozen plasma-first approach is independently associated with improved survival in severely injured patients undergoing massive transfusion. J Trauma Acute Care Surg, 2026.PMID 42275580